Published in J Infect Dis on February 01, 1996
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol (1998) 2.48
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol (2000) 1.88
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. Br J Ophthalmol (2001) 1.39
In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest (1998) 1.36
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol (2002) 1.19
Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol (2011) 1.17
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol (2005) 1.06
Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol (1999) 1.03
Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Clin Exp Immunol (1999) 0.98
Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol (2003) 0.98
Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol (2001) 0.96
Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol (2003) 0.92
Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages. Retrovirology (2007) 0.91
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab Immunol (2002) 0.91
Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol (1999) 0.90
CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis. Front Immunol (2015) 0.90
Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy. Clin Diagn Lab Immunol (2003) 0.88
Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects. Clin Exp Immunol (1999) 0.87
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect (1999) 0.87
Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol (1998) 0.85
Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency. PLoS One (2013) 0.83
Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clin Exp Immunol (2003) 0.83
Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Front Immunol (2013) 0.82
Single-cell profiling of lineage determining transcription factors in antigen-specific CD4(+) T cells reveals unexpected complexity in recall responses during immune reconstitution. Immunol Cell Biol (2017) 0.82
Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients. Clin Exp Immunol (1998) 0.81
Prospects for immune reconstitution in HIV-1 infection. Clin Exp Immunol (2002) 0.81
In vitro hydroxyurea decreases Th1 cell-mediated immunity. Clin Diagn Lab Immunol (2001) 0.81
Role of CD8(+) T cells in triggering reversal reaction in HIV/leprosy patients. Immunology (2013) 0.79
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines (2008) 0.78
T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol (2000) 0.78
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother (2001) 0.77
SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology (2011) 0.76
Characteristics of hepatitis C virus infection in HIV-infected people. Can J Infect Dis (2001) 0.75
Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report. BMC Infect Dis (2015) 0.75
Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for. Genitourin Med (1997) 0.75
The role of HIV-proteinase inhibitors. Genitourin Med (1996) 0.75
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br (1996) 7.44
Questionnaire on the perceptions of patients about total knee replacement. J Bone Joint Surg Br (1998) 7.20
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Adverse effects of antiretroviral therapy. Lancet (2000) 4.84
Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet (1985) 4.83
The roles of individual polyoma virus early proteins in oncogenic transformation. Nature (1982) 4.57
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
The 2010 Royal Australasian College of Physicians' policy statement 'Circumcision of infant males' is not evidence based. Intern Med J (2012) 4.15
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Cloning, sequencing and transcriptional control of the Schizosaccharomyces pombe cdc10 'start' gene. EMBO J (1985) 3.87
Questionnaire on the perceptions of patients about shoulder surgery. J Bone Joint Surg Br (1996) 3.72
Expression of the large T protein of polyoma virus promotes the establishment in culture of "normal" rodent fibroblast cell lines. Proc Natl Acad Sci U S A (1983) 3.65
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee--the MOVE consensus. Rheumatology (Oxford) (2004) 3.38
Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet (1985) 3.33
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 3.22
Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) (2004) 3.22
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Primary HIV infection: host responses and intervention strategies. AIDS (1991) 2.80
Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med (1992) 2.65
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet (1992) 2.60
Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet (1998) 2.43
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med (2005) 2.33
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.23
Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science (1983) 2.21
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS (2001) 2.17
HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14
Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral. Rheumatology (Oxford) (2005) 2.07
Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet (1998) 2.04
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Construction and functional characterization of polyomavirus genomes that separately encode the three early proteins. J Virol (1984) 2.02
Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust (1989) 2.02
The CALM1 core promoter polymorphism is not associated with hip osteoarthritis in a United Kingdom Caucasian population. Osteoarthritis Cartilage (2005) 1.99
Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med (2007) 1.95
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis (2000) 1.91
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88
Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor. J Virol (1995) 1.85
CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS (1991) 1.85
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78
Ribavirin: a role in HIV infection? J Acquir Immune Defic Syndr (1990) 1.74
Transcription of the cdc2 cell cycle control gene of the fission yeast Schizosaccharomyces pombe. EMBO J (1986) 1.73
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis (1999) 1.70
The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis (1991) 1.69
Comparison of measures to assess outcomes in total hip replacement surgery. Qual Health Care (1996) 1.60
A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) (2002) 1.58
Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise. Blood (1993) 1.54
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet (2000) 1.51
Gangliosides expressed in human breast cancer. Cancer Res (1996) 1.49
The value of phenobarbital in the child who has had a single febrile seizure: a controlled prospective study. Pediatrics (1977) 1.46
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46
The problem of open-sea navigation: the migration of the green turtle to ascension island. J Theor Biol (1969) 1.42
The assessment of shoulder instability. The development and validation of a questionnaire. J Bone Joint Surg Br (1999) 1.42
The neurological features of early and 'latent' human immunodeficiency virus infection. Aust N Z J Med (1989) 1.42
Syringe HIV seroprevalence and behavioural and demographic characteristics of intravenous drug users in Sydney, Australia, 1987. AIDS (1988) 1.41
Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis (1998) 1.41
Bile acid malabsorption in HIV infected patients with chronic diarrhoea. Aust N Z J Med (1996) 1.40
Survival of patients with the acquired immunodeficiency syndrome in Australia. Med J Aust (1989) 1.39
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
If it's the virus, why aren't we measuring it? Med J Aust (1995) 1.38
A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol (1998) 1.38
Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet (1987) 1.37
Transmission of triple-class, drug-resistant HIV-1 in Australia. Intern Med J (2010) 1.37
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35
Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol (1994) 1.34
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med (2003) 1.34
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis (1997) 1.33
Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess (1998) 1.32
Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr (2001) 1.32
Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet (1997) 1.30
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med (2007) 1.29
Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med (1998) 1.29
Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol (2000) 1.29
Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis (1990) 1.26
HIV infection of rectal mucosa. Lancet (1988) 1.22
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
The benefits of using patient-based methods of assessment. Medium-term results of an observational study of shoulder surgery. J Bone Joint Surg Br (2001) 1.20
Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. J Nutr (2001) 1.20
Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International. Osteoarthritis Cartilage (2006) 1.19